Literature DB >> 19714456

Malignant hyperthermia susceptibility in a patient with mitochondrial disorder.

Josef Finsterer1, Andrea Michalek-Sauberer, Romana Höftberger.   

Abstract

Occasionally, patients with mitochondrial disorder (MID) develop malignant hyperthermia (MH)-like reactions or show an abnormal halothane-caffeine in-vitro contracture test. In a 66 year old Caucasian male with facial dysmorphism, epilepsy, chronic muscle cramps, repeatedly elevated creatine-kinase, Dupuytren contracture, and hypertrophic cardiomyopathy, a MID was found upon the clinical presentation, blood chemical investigations, and the muscle biopsy findings. Upon request of the anesthesiologists prior to surgery of a hernia cicatrices a halothane-caffeine in-vitro contracture test was carried out according to the protocol of the European MH Group (EMHG), showing abnormal hypercontractility to halothane and caffeine, resulting in the diagnosis susceptible MH according to the EMHG guidelines. Subsequent general anesthesia was carried out without complications by avoiding volatile anesthetics and succinylcholine. In the past the patient had already tolerated four procedures under general anesthesia, without any complication. MIDs may be associated with an abnormal halothane-caffeine in-vitro contracture test. Though previous general anesthesias had been carried out without major complications, it cannot be ruled out that MH-like manifestations may develop during future anesthesias if trigger agents are not avoided.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19714456     DOI: 10.1007/s11011-009-9148-3

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  14 in total

1.  Positive malignant hyperthermia susceptibility in vitro test in a patient with mitochondrial myopathy and myoadenylate deaminase deficiency.

Authors:  Ruth M Fricker; Thomas Raffelsberger; Sigrid Rauch-Shorny; Josef Finsterer; Clemens Müller-Reible; Hermann Gilly; Reginald E Bittner
Journal:  Anesthesiology       Date:  2002-12       Impact factor: 7.892

2.  Anaesthetic management of labour and delivery in the parturient with mitochondrial myopathy.

Authors:  O P Rosaeg; S Morrison; J P MacLeod
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 5.063

3.  In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.

Authors:  H Ording; V Brancadoro; S Cozzolino; F R Ellis; V Glauber; E F Gonano; P J Halsall; E Hartung; J J Heffron; L Heytens; G Kozak-Ribbens; H Kress; R Krivosic-Horber; F Lehmann-Horn; W Mortier; Y Nivoche; E Ranklev-Twetman; S Sigurdsson; M Snoeck; P Stieglitz; V Tegazzin; A Urwyler; F Wappler
Journal:  Acta Anaesthesiol Scand       Date:  1997-09       Impact factor: 2.105

4.  Are myotonias and periodic paralyses associated with susceptibility to malignant hyperthermia?

Authors:  F Lehmann-Horn; P A Iaizzo
Journal:  Br J Anaesth       Date:  1990-11       Impact factor: 9.166

5.  [Anesthesia in mitochondrial encephalomyopathies].

Authors:  A Thiel; M Ritzka; G Saur
Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther       Date:  2001-07       Impact factor: 0.698

6.  Pathological findings in 165 patients explored for malignant hyperthermia susceptibility.

Authors:  D Figarella-Branger; G Kozak-Ribbens; L Rodet; M Aubert; J Borsarelli; P J Cozzone; J F Pellissier
Journal:  Neuromuscul Disord       Date:  1993 Sep-Nov       Impact factor: 4.296

7.  Anesthesia for a child with complex I respiratory chain enzyme deficiency.

Authors:  E W Cheam; L A Critchley
Journal:  J Clin Anesth       Date:  1998-09       Impact factor: 9.452

Review 8.  Mitochondrial disorders and general anaesthesia: a case series and review.

Authors:  E J Footitt; M D Sinha; J A J Raiman; A Dhawan; S Moganasundram; M P Champion
Journal:  Br J Anaesth       Date:  2008-02-19       Impact factor: 9.166

Review 9.  [Chronic rhabdomyolysis disclosing mitochondriopathy and malignant hyperthermia susceptibility].

Authors:  F Etcharry-Bouyx; I Sangla; G Serratrice
Journal:  Rev Neurol (Paris)       Date:  1995-10       Impact factor: 2.607

Review 10.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.